邻乙氧基甲苯 | 614-71-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 邻乙氧基甲苯
• 英文名称: 2-ethoxytoluene
• 英文别名: o-ethoxytoluene；ortho-ethoxytoluene；ethoxytoluene；2-methyl-phenetole；2-Methyl-phenetol；Aethyl-o-tolyl-aether；2-Aethoxy-1-methyl-benzol；Aethyl-o-kresyl-aether；o-Kresol-aethylaether；2-Aethoxy-toluol；1-ethoxy-2-methyl-benzene；1-Ethoxy-2-methylbenzene
• CAS: 614-71-1
• 化学式: C₉H₁₂O
• mdl: MFCD00130073
• 分子量: 136.194
• InChiKey: JWMKUKRBNODZFA-UHFFFAOYSA-N

物化性质

• 熔点：
  184-184.5 °C
• 沸点：
  184°C (estimate)
• 密度：
  0.9592
• 介电常数：
  3.9（20.0℃）
• 保留指数：
  1054.5

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  邻乙氧基甲苯 生成 6-ethoxy-toluene-3-sulfonic acid amide
  参考文献：
  名称：

  Identification of Organic Compounds. III. Chlorosulfonic Acid as a Reagent for the Characterization of Aromatic Ethers^1,2

  摘要：

  DOI：

  10.1021/ja01860a049
• 作为产物：
  描述：

  邻甲苯胺 生成 邻乙氧基甲苯
  参考文献：
  名称：

  Remsen; Orndorff, American Chemical Journal, 1887, vol. 9, p. 394

  摘要：

  DOI：

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• [EN] SPIROCYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES SPIROCYCLIQUES UTILES COMME INHIBITEURS DU VIH
  申请人：MERCK SHARP & DOHME

  公开号：WO2016094198A1

  公开（公告）日：2016-06-16

  The present invention relates to Spirocyclic Heterocycle Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, B, X, R1, R2, R3 and R4 are as defined herein. The present invention also relates to compositions comprising at least one Spirocyclic Heterocycle Compound, and methods of using the Spirocyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.

  本发明涉及式(I)的螺环杂环化合物及其药学上可接受的盐，其中A、B、X、R1、R2、R3和R4如本文所定义。本发明还涉及包含至少一种螺环杂环化合物的组合物，以及使用螺环杂环化合物治疗或预防受试者的HIV感染的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• [EN] SPIRO[CYCLOPENTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS<br/>[FR] DÉRIVÉS SPIRO[CYCLOPENTANE-1,3'-INDOLIN]-2'-ONE UTILISÉS EN TANT QU'INHIBITEURS DE BROMODOMAINES
  申请人：AURIGENE DISCOVERY TECH LTD

  公开号：WO2018109650A1

  公开（公告）日：2018-06-21

  The present invention provides spiro[cyclopentaneane-1,3'-indolin]-2'-one derivatives of formula (I), which are therapeutically useful, more particularly as bromodomain inhibitors. (I) wherein Cy, R1, R2, L and 'm' have the meaning given in the specification, and pharmaceutically acceptable salts or pharmaceutically acceptable stereoisomers thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use as bromodomain inhibitors in the treatment and prevention of the associated diseases or disorders. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the spiro[cyclopentane-1,3'-indolin]-2'-one derivatives of formula (I), together with a pharmaceutically acceptable carrier, diluent or excipient therefore.

  本发明提供了式(I)的螺[环戊烷-1,3'-吲哚]-2'-酮衍生物，其在治疗上具有用途，更具体地作为溴结构域抑制剂。其中Cy、R1、R2、L和'm'在说明书中给出的含义，以及它们的药学上可接受的盐或药学上可接受的立体异构体，在治疗和预防疾病或紊乱方面具有用途，特别是它们作为溴结构域抑制剂在治疗和预防相关疾病或紊乱方面的用途。本发明还提供了该化合物的制备以及包括至少一种式(I)的螺[环戊烷-1,3'-吲哚]-2'-酮衍生物的药物配方，以及药学上可接受的载体、稀释剂或赋形剂。
• FLAP MODULATORS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20150259357A1

  公开（公告）日：2015-09-17

  The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R 1 , R 2 , R 3 , R 3 ′, L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention

  本发明涉及式（I）的化合物，或其形式，其中环A，R1，R2，R3，R3'，L，W和V如本文所定义，可用作FLAP调节剂。该发明还涉及包含式（I）化合物的药物组合物。制备和使用式（I）化合物的方法也属于本发明的范围。

表征谱图